- Home
- MRM vs INDP Comparison
MRM vs INDP Comparison
Compare MRM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- INDP
- Stock Information
- Founded
- MRM 2000
- INDP 2000
- Country
- MRM Japan
- INDP United States
- Employees
- MRM N/A
- INDP N/A
- Industry
- MRM Other Consumer Services
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- INDP Health Care
- Exchange
- MRM Nasdaq
- INDP Nasdaq
- Market Cap
- MRM 12.2M
- INDP 10.2M
- IPO Year
- MRM 2020
- INDP N/A
- Fundamental
- Price
- MRM $0.99
- INDP $0.84
- Analyst Decision
- MRM
- INDP Strong Buy
- Analyst Count
- MRM 0
- INDP 2
- Target Price
- MRM N/A
- INDP $8.50
- AVG Volume (30 Days)
- MRM 95.4K
- INDP 25.3K
- Earning Date
- MRM 01-01-0001
- INDP 03-12-2025
- Dividend Yield
- MRM N/A
- INDP N/A
- EPS Growth
- MRM N/A
- INDP N/A
- EPS
- MRM N/A
- INDP N/A
- Revenue
- MRM $44,462,062.00
- INDP N/A
- Revenue This Year
- MRM N/A
- INDP N/A
- Revenue Next Year
- MRM N/A
- INDP N/A
- P/E Ratio
- MRM N/A
- INDP N/A
- Revenue Growth
- MRM 2.80
- INDP N/A
- 52 Week Low
- MRM $0.90
- INDP $0.81
- 52 Week High
- MRM $8.39
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- MRM 33.16
- INDP 39.07
- Support Level
- MRM $0.93
- INDP $0.86
- Resistance Level
- MRM $1.05
- INDP $1.06
- Average True Range (ATR)
- MRM 0.08
- INDP 0.08
- MACD
- MRM 0.06
- INDP 0.00
- Stochastic Oscillator
- MRM 25.53
- INDP 12.80
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.